LIVN — LivaNova PLC
NASDAQ · Healthcare · Medical Devices
$81.91
+$1.75 (+2.18%)
LivaNova PLC (LIVN) is a medical devices company listed on NASDAQ. It is led by Vladimir A. Makatsaria, based in 20 Eastbourne Terrace, London, United Kingdom, W2 6LG, with about 3,300 employees. LivaNova PLC, a medical technology company, designs, develops, manufactures, markets, and sells products, therapies, and services in the United States, the United Kingdom, Germany, France, Italy, the Netherlands, Spain, Belgium, Poland, Sweden, Switzerland, Austria, Norway, Portugal, Finland, Denmark, and internationally. The company operates in two segments, Cardiopulmonary and Neuromodulation. The Cardiopulmonary segment provides cardiopulmonary products, including heart-lung machines, oxygenators, autotransfusion systems, perfusion tubing systems, cannulae, and other related accessories, as well as services related products. The Neuromodulation segment offers VNS Therapy System, an implantable pulse generator and connective lead that stimulates the vagus nerve, surgical equipment to assist with the implant procedure, and equipment and instruction manuals; and devices that deliver neuromodulation therapy for treating drug-resistant epilepsy and difficult-to-treat depression. This segment also includes the development and clinical testing of LivaNova's aura6000 system for treating obstructive sleep apnea. It serves perfusionists, neurologists, neurosurgeons, and other healthcare professionals, hospitals, and other medical institutions and healthcare providers. The company sells its medical devices through a combination of direct sales representatives, agents, and independent distributors. LivaNova PLC was incorporated in 2015 and is headquartered in London, the United Kingdom.
Latest reported LIVN revenue for 2025-09-30 was $357.8M. Net income was $26.8M. Revenue was up 1.5% from 2025-06-30 to 2025-09-30. LIVN currently screens at market cap $4.40B and trailing P/E 40.8.
Use this LIVN page for company research — sector, financials, and the latest filing takeaway — not a live tape. The session quote (last, range, volume) lives on the LIVN quote page. Cached 10-K, 10-Q, 8-K, and Form 4 exhibits are on the LIVN SEC filings page. Lician reads the product cache first so this HTML stays unique to LivaNova PLC even when a live quote feed is slow.
About LivaNova PLC
LivaNova PLC, a medical technology company, designs, develops, manufactures, markets, and sells products, therapies, and services in the United States, the United Kingdom, Germany, France, Italy, the Netherlands, Spain, Belgium, Poland, Sweden, Switzerland, Austria, Norway, Portugal, Finland, Denmark, and internationally. The company operates in two segments, Cardiopulmonary and Neuromodulation. The Cardiopulmonary segment provides cardiopulmonary products, including heart-lung machines, oxygenators, autotransfusion systems, perfusion tubing systems, cannulae, and other related accessories, as well as services related products. The Neuromodulation segment offers VNS Therapy System, an implantable pulse generator and connective lead that stimulates the vagus nerve, surgical equipment to assist with the implant procedure, and equipment and instruction manuals; and devices that deliver neuromodulation therapy for treating drug-resistant epilepsy and difficult-to-treat depression. This segment also includes the development and clinical testing of LivaNova's aura6000 system for treating obstructive sleep apnea. It serves perfusionists, neurologists, neurosurgeons, and other healthcare professionals, hospitals, and other medical institutions and healthcare providers. The company sells its medical devices through a combination of direct sales representatives, agents, and independent distributors. LivaNova PLC was incorporated in 2015 and is headquartered in London, the United Kingdom.
LIVN Key Statistics
Market Cap
$4.40B
Volume
196,647
Previous Close
$78.26
Day Range
$77.90 – $79.51
P/E Ratio
40.83
P/B Ratio
3.60
EPS
$1.16
Revenue
$1.25B
Net Income
$63.23M
Gross Profit
$0.00
Free Cash Flow
$0.00
Revenue Growth
+8.7%
Profit Margin
5.0%
Employees
3,300
LIVN Financials
Annual income statement in USD. Latest reported periods first.
| Line | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|
| Revenue | $1.25B | $1.15B | $1.02B | $270.06M |
| Cost of Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross Profit | $0.00 | $0.00 | $0.00 | $0.00 |
| Operating Income | $0.00 | $0.00 | $0.00 | $0.00 |
| Net Income | $63.23M | $17.55M | -$86.25M | -$5.13M |
| EPS (Diluted) | $1.16 | $0.32 | -$1.61 | -$0.10 |
Total Assets
$2.51B
Total Debt
$0.00
Shareholders' Equity
$0.00
Cash & Equivalents
$428.86M
Operating Cash Flow
$183.04M
Free Cash Flow
$0.00
LivaNova PLC Company Information
- CEO & Director
- Vladimir A. Makatsaria
- Headquarters
- 20 Eastbourne Terrace, London, United Kingdom, W2 6LG
- Website
- www.livanova.com
- Phone
- 44 20 3325 0660
- IPO / Founded
- 1993-02-10
- Sector
- Healthcare
- Industry
- Medical Devices